Despite significant advancements in understanding the biology of patients with HER2-low and HER2-ultralow BC and the promising potential of ADCs, heterogeneous findings, and clinical outcomes across studies underscore the need for a comprehensive summary of existing research. The gene discussed is ERBB2; the disease is breast cancer.